Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Fecal Microbiota Transplantation for Drug-refractory Hepatic Encephalopathy After TIPS
NCT07454408Phase 2Not yet recruiting
- Sponsor
- Air Force Medical University
- Start
- Mar 2026
- Primary completion
- Jun 2028
- Modality
- Live Biotherapeutic Products
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in hepatic encephalopathy (HE) comparing Fecal Microbiota Transplantation Group with Placebo Control Group (2 arms). Primary endpoint: Incidence and severity of treatment-related adverse events and serious adverse events at 6 months. Planned start Mar 2026; status: not yet recruiting.
02
Drugs
Fecal Microbiota Transplantation Capsule
03
Conditions
hepatic encephalopathy (HE)
Beyond the preview
Go deeper on NCT07454408.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07454408.